{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:23:40Z","timestamp":1740374620305,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1007\/bf03190589","type":"journal-article","created":{"date-parts":[[2010,8,6]],"date-time":"2010-08-06T10:28:31Z","timestamp":1281090511000},"page":"145-152","source":"Crossref","is-referenced-by-count":4,"title":["A tolerability andpharmacokinetic study of a newinjectable formulation of disodium clodronate in healthyfemale volunteers"],"prefix":"10.1007","volume":"29","author":[{"given":"Gianluigi","family":"Poli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrizia","family":"Mariotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario Ermanno","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Acerbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"BF03190589_CR1","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00003495-199142060-00003","volume":"42","author":"H. Fleisch","year":"1991","unstructured":"Fleisch H., Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs, 42 919\u2013944 (1991).","journal-title":"Drugs"},{"key":"BF03190589_CR2","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1107\/S0567740879005938","volume":"35","author":"B.L. Barnett","year":"1979","unstructured":"Barnett B.L., Strickland L.C., Structure of disodium dihydrogen 1-hydroxyethylidenediphosphonate tetrahydrate: a bone growth regulator. Acta Crystallogr. B. 35 1212\u20131214 (1979).","journal-title":"Acta Crystallogr. B."},{"key":"BF03190589_CR3","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/BF02547227","volume":"11","author":"A. Jung","year":"1973","unstructured":"Jung A., Bisaz S., Fleisch H., The binding of pyrophosphate and two diphosphonate on hydroxyapatite crystals. Calcif. Tissue Res., 11: 269\u2013280 (1973).","journal-title":"Calcif. Tissue Res."},{"issue":"1","key":"BF03190589_CR4","first-page":"79","volume":"8","author":"S. Ljunghall","year":"1987","unstructured":"Ljunghall S., Rastad J., Akerstrom G., Comparative effects of calcitonin and clodronate in hypercalcaemia. Bone, 8(1) S79\u201383 (1987).","journal-title":"Bone"},{"issue":"4","key":"BF03190589_CR5","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2165\/00003495-199346040-00003","volume":"46","author":"S. Patel","year":"1993","unstructured":"Patel S., Lyons A.R., Hosking D.J., Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use. Drugs, 46(4) 594\u2013617 (1993).","journal-title":"Drugs"},{"issue":"2","key":"BF03190589_CR6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S8756-3282(98)00154-9","volume":"24","author":"M. Rossini","year":"1999","unstructured":"Rossini M., Braga V., Gatti D., et al., Intramuscular clodronate therapy in postmenopausal osteoporosis. Bone, 24(2) 125\u20139 (1999).","journal-title":"Bone"},{"issue":"4","key":"BF03190589_CR7","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S8756-3282(95)00262-6","volume":"17","author":"S. Adami","year":"1995","unstructured":"Adami S., Passen M., Ortolani S., et al., Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone, 17 (4) 383\u201390 (1995).","journal-title":"Bone"},{"issue":"8678\u20138679","key":"BF03190589_CR8","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0140-6736(89)92927-9","volume":"2","author":"J.Y. Reginster","year":"1989","unstructured":"Reginster J.Y., Lecart M.P., Deroisy R., et al., Prevention of postmenopausal bone loss by tiludronate. Lancet, 2(8678\u20138679) 1469\u201371 (1989).","journal-title":"Lancet"},{"issue":"18","key":"BF03190589_CR9","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1056\/NEJM199005033221803","volume":"322","author":"T. Storm","year":"1990","unstructured":"Storm T., Thamsborg G., Steiniche T., et al., Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med., 322(18) 1265\u201371 (1990).","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"BF03190589_CR10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0169-6009(89)90095-0","volume":"5","author":"R. Valkema","year":"1989","unstructured":"Valkema R., Vismans F.J., Papapoulos S.E., et al. Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. Bone Miner., 5(2) 183\u201392 (1989).","journal-title":"Bone Miner."},{"issue":"2","key":"BF03190589_CR11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM199007123230201","volume":"323","author":"N.B. Watts","year":"1990","unstructured":"Watts N.B., Harris S.T., Genant H.K., et al., Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N. Engl. J. Med., 323(2) 73\u20139 (1990).","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"BF03190589_CR12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/jbmr.5650020506","volume":"2","author":"S. Adami","year":"1987","unstructured":"Adami S., Bolzicco G.P., Rizzo A., et al., The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy. Bone Miner., 2(5) 395\u2013404 (1987).","journal-title":"Bone Miner."},{"issue":"6","key":"BF03190589_CR13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/0221-8747(84)90012-2","volume":"5","author":"S. Adami","year":"1984","unstructured":"Adami S., Guarrera G., Salvagno G. et al., Sequential treatment of Paget\u2019s disease with human calcitonin and dichloromethylene diphosphonate (C12MDP). Metab. Bone Dis. Relat. Res., 5(6) 265\u20137 (1984).","journal-title":"Metab. Bone Dis. Relat. Res."},{"issue":"6","key":"BF03190589_CR14","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1016\/S0022-5347(17)47663-4","volume":"134","author":"S. Adami","year":"1985","unstructured":"Adami S., Salvagno G., Guarrera G. et al., Dichloromethylene-diphosphonate in patients with prostatic carcinoma metastatic to the skeleton. J. Urol., 134(6) 1152\u20134 (1985).","journal-title":"J. Urol."},{"issue":"6","key":"BF03190589_CR15","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00003495-199142060-00003","volume":"42","author":"H. Fleisch","year":"1991","unstructured":"Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs, 42 (6) 919\u201344 (1991).","journal-title":"Drugs"},{"key":"BF03190589_CR16","unstructured":"Clodronate: a new perspective in thetreatment of neoplastic bone disease. Proceedings of a meeting. Helsinki. Bone, 8(Suppl 1) :S 1\u201386 (1987)."},{"issue":"8682","key":"BF03190589_CR17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/0140-6736(90)90043-5","volume":"335","author":"J.A. Kanis","year":"1990","unstructured":"Kanis J.A., McCloskey E.V., Paterson A.H., Use of diphosphonates in hypercalcaemia due to malignancy. Lancet, 335(8682) 170\u20131 (1990).","journal-title":"Lancet"},{"issue":"8444","key":"BF03190589_CR18","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(85)92253-6","volume":"1","author":"A.J. Yates","year":"1985","unstructured":"Yates A.J., Percival R.C., Gray R.E. et al., Intravenous clodronate in the treatment and retreatment of Paget\u2019s disease of bone. Lancet, 1 (8444) 1474\u20137 (1985).","journal-title":"Lancet"},{"issue":"2","key":"BF03190589_CR19","first-page":"23","volume":"3","author":"J.A. Kanis","year":"1993","unstructured":"Kanis J.A., McCloskey E.V., Sirtori P. et al., Rationale for the use of clodronate in osteoporosis. Osteoporos. Int., 3(2) S23\u20138 (1993).","journal-title":"Int."},{"issue":"2","key":"BF03190589_CR20","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s002239900315","volume":"61","author":"T.S. Kaastad","year":"1997","unstructured":"Kaastad T.S., Reikeras O., Madsen J.E. et al., Effects of clodronate on cortical and trabecular bone in ovariectomized rats on a low calcium diet. Calcif. Tissue Int., 61 (2) 158\u201364 (1997).","journal-title":"Calcif. Tissue Int."},{"issue":"2","key":"BF03190589_CR21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/8756-3282(95)00439-4","volume":"18","author":"V.T. Lepola","year":"1996","unstructured":"Lepola V.T.. Hannuniemi R., Kippo K., et al., Long-term effects of clodronate on growing rat bone. Bone, 18(2) 191\u20136 (1996).","journal-title":"Bone"},{"issue":"4","key":"BF03190589_CR22","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1172\/JCI110331","volume":"68","author":"P. Minaire","year":"1981","unstructured":"Minaire P., Berard E., Meunier P.J., et al., Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients. J. Clin. Invest. 68(4) 1086\u201392 (1981).","journal-title":"J. Clin. Invest."},{"issue":"2","key":"BF03190589_CR23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"J.H. Lin","year":"1996","unstructured":"Lin J.H., Bisphosphonates: a review of their pharmacokinetic properties. Bone, 18(2)75\u201385 (1996).","journal-title":"Bone"},{"issue":"3","key":"BF03190589_CR24","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","volume":"14","author":"S. Adami","year":"1996","unstructured":"Adami S., Zamberlan N., Adverse effects of bisphosphonates. A comparative review. Drug Saf., 14(3) 158\u201370 (1996).","journal-title":"Drug Saf."},{"issue":"2","key":"BF03190589_CR25","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/8756-3282(95)00442-4","volume":"18","author":"P. Filipponi","year":"1996","unstructured":"Filipponi P., Cristallini S., Rizzello E. et al., Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial. Bone, 18(2) 179\u201384 (1996).","journal-title":"Bone"},{"issue":"5","key":"BF03190589_CR26","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jbmr.5650100505","volume":"10","author":"P. Filipponi","year":"1995","unstructured":"Filipponi P., Pedetti M., Fedeli L. et al., Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy. J. Bone Miner. Res., 10 (5) 697\u2013703 (1995).","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"BF03190589_CR27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1359\/jbmr.1997.12.1.103","volume":"12","author":"J.E. Heikkinen","year":"1997","unstructured":"Heikkinen J.E., Seiander K.S., Laitinen K., et al., Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss. J. Bone Miner. Res., 12(1) 103\u2013110 (1997).","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"BF03190589_CR28","first-page":"33","volume":"23","author":"S. Gnudi","year":"2001","unstructured":"Gnudi S., Lisi L., Fini M., et al., Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women. Int. J. Tissue React., 23(1), 33\u20137 (2001).","journal-title":"Int. J. Tissue React."},{"key":"BF03190589_CR29","unstructured":"CTFA technical guidelines III. \u201cPharmacology and toxicology, safety testing guidelines. Guidelines forevaluating contact sensitisation potential\u201d. The Cosmetic, Toiletry and Fragrance Association Inc. Washington D.C., USA., Curry (Ed.), pp. 7\u20139 G.N. Mc Ewen Jr., Anita S. (1981)."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03190589.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03190589\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03190589","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,23]],"date-time":"2025-02-23T22:16:45Z","timestamp":1740349005000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03190589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["BF03190589"],"URL":"https:\/\/doi.org\/10.1007\/bf03190589","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"type":"print","value":"0378-7966"},{"type":"electronic","value":"2107-0180"}],"subject":[],"published":{"date-parts":[[2004,6]]}}}